Category Archive: Drug development

Aug 03

Antimicrobial Development: Getting Things Started

LGC Microbiology overview

Developing antimicrobials is a war of attrition, with an unfortunate number of potential compounds falling at one of the many hurdles along the way. I’m keen to support the process and speaking as someone who is a pre-clinical in vitro drug development specialist, the obvious way for me to help is to encourage more molecules …

Continue reading »

May 26

Accurate MIC endpoints with automation

LGC-Anti-infective-drug-development_services

LGC’s drug development team regularly assess new methods to refine and strengthen our existing analytical services across all disciplines.   An old-school stalwart of microbiology testing, minimum inhibitory concentration (MIC) testing identifies the lowest concentration of a substance that prevents visible growth of a bacterial strain.   The MIC is the bacteria’s tipping point and …

Continue reading »

Apr 05

The new ICH Q3D Elemental Impurities Guideline – nothing to fear if you act now

The ICH Q3D Guideline on Elemental Impurities has been adopted by the European and US Pharmacopoeias, meaning that by the end of 2017 all new and existing products in Europe and the US will need to be assessed. Initially it was thought that every marketed product would require full testing for trace metals. However, the …

Continue reading »

Jan 31

10 million people will die of bacterial infections in 2050, and each year after that

  Article by: Ed Siegwart    Antibiotic awareness European Antibiotic Awareness Day (EAAD) took place on 18 November, in the middle of World Antibiotic Awareness Week and reminded us of the shocking statistic that if no new antibiotics are successfully developed then 10 million people will die of bacterial infections in 2050, and each year after …

Continue reading »

Dec 12

Foreign particulate matter in pharmaceuticals

There has been a recent rise in the number of pharmaceutical product recalls due to the presence of Foreign Particulate Matter (FPM), and its effect on product efficacy and safety. FPM is either inherent (from the product itself), intrinsic (from the production process), or extrinsic (contaminating particles from outside). There is a regulatory requirement for …

Continue reading »

Jul 01

Discover what inorganic mass spectrometry can do

Inorganic mass spectrometry has a wide range of potential applications, from reference material development to nanoparticle analysis or pharmaceutical testing, as will be showcased by LGC scientists at the 18th Biennial National Atomic Spectroscopy Symposium (BNASS) on 4 to 6 July 2016. BNASS is the biennial meeting of the RSC Atomic Spectroscopy Group and provides …

Continue reading »

Apr 26

In vitro antimicrobial efficacy testing: potential pitfalls and future methods

LGC supports the antimicrobial drug pipeline

Antimicrobial resistance (AMR) is a global issue, which already causes significant loss of life and will continue to get worse as further resistance evolves. By 2050, it is anticipated that due to AMR alone, 10 million people will die each year, more than currently die from diseases like cancer.   Antimicrobial drug pipeline One of …

Continue reading »

Feb 18

Quantitation of low level impurities using LC-MS/MS in GMP analysis

Register for the LGC webinar on In vitro antimicrobial efficacy testing

LC-MS/MS has been the technique of choice for trace organic analysis in most areas of analytical chemistry for over a decade and is now slowly but steadily becoming so in GMP pharmaceutical analysis. LC-MS/MS offers unrivalled sensitivity and selectivity as well as speed of analysis. The technique is able to routinely quantify down to the …

Continue reading »

Jan 22

Little to LARGE: LC-MS/MS peptide method development for small molecule specialists

The development of LC-MS/MS methods for the quantitation of large molecules within biological matrices can help to overcome some of the challenges associated with immunoassay-based analyses. For example, the need to raise new antibodies against novel analytes, poor specificity due to cross reactivity with similar compounds, and for radioimmunoassays the additional safety considerations. LC-MS/MS method …

Continue reading »

Jul 10

Supercharging reagents – revving up peptide LC-MS analyses

Over the past 5 years, LC-MS has (arguably) become the technique of choice to quantify peptides in biological matrices. The benefits of using LC-MS as a quantitative technique are significant, however, there is one drawback – low sensitivity. The acquisition of multiple numbers of charge states for peptides in the MS source can result in …

Continue reading »

Older posts «

%d bloggers like this: